Language quotas for Ukraine’s TV will only fuel tensions — media groupSociety & Culture May 24, 8:49
Syrian troops repel militant attack west of Palmyra — mediaWorld May 24, 8:08
Foreign businesses lack state guarantees for their investment in RussiaBusiness & Economy May 24, 7:55
Russian 'soldier of the future' combat gear tested in SyriaMilitary & Defense May 24, 6:41
London police say investigation into Manchester blast ‘fast-moving’World May 24, 5:21
Investigators release Gogol-Center artistic director after questioningSociety & Culture May 24, 2:32
London may be among contenders for 2018 FIDE chess world championshipSport May 24, 2:29
Putin meets with visiting Philippine leaderRussian Politics & Diplomacy May 24, 0:15
Mechanism of alerting on cyberattacks practically never used by US — spokespersonWorld May 23, 22:19
MOSCOW, September 02. /ITAR-TASS/. The Russian government’s foreign investment commission has cleared US company Abbot purchase of Russia’s major pharmaceutical producer Veropharm for $650 million, Director of the Federal Antimonopoly Service Igor Artemyev said Tuesday.
“The first deal, which has been cleared by the commission today, is large US company Abbot buying Veropharm that produces many important medicines for the treatment of oncological diseases, acute leukemia and others,” Artemyev said.
He also said the sum of the deal comprises the cost of Veropharm and its affiliates, while $250 million more will be allocated for the construction of new production sites increasing the production’s localization.
On June 24, Abbott said that it will acquire Veropharm from its largest shareholder Roman Avdeyev for $13.6-17 billion rubles. The purchase price will depend on the stake which Avdeyev’s holding Garden Hills, which currently owns about 81% in Veropharm, can consolidate at the moment when the contract is signed.
Abbot also agreed to repay Veropharm’s debts of 4.7 billion rubles, or $136 million.